TET2 and myeloproliferative neoplasm: CMML is the most common and thus the best genetically characterized MDS/MPN, with >90% patients showing ≥1 mutation frequently affecting TET2 (60%), SRSF2 (50%) and ASXL1 (45%) (Figure 1B).